A desensitization protocol for the mAb cetuximab.
Jerath
Maya R
MR
Kwan
Mildred
M
Kannarkat
Mily
M
Mirakhur
Beloo
B
Carey
Lisa
L
Valgus
John
J
Platts-Mills
Thomas A E
TA
Tarrant
Teresa K
TK
D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy*; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects; D000068818:Cetuximab; D003888:Desensitization, Immunologic / Q000379:methods*; D004342:Drug Hypersensitivity / Q000517:prevention & control*; D005260:Female; D006801:Humans; D008875:Middle Aged
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D016190:Carboplatin; D000068818:Cetuximab